Diligence memo · auto-generated · as of July 2, 2026
Gemin X Pharmaceuticals Inc
Gemin X Pharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Gemin X Pharmaceuticals Inc operates in Biotechnology, based in Malvern.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Gemin X Pharmaceuticals Inc has raised $13M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $9.3M on 2009-05-29.
Most recent recorded round closed around 2010-05-07.
Valuation (modeled)modeled
Provath models Gemin X Pharmaceuticals Inc at approximately $142M (range $4.3M–$770M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.71× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era. Within the normal band (71% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 16.2 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 61% of Biotechnology peers (4293 compared).
Modeled value ranks above 65% of those peers.
Closest niche peers: Tobira Therapeutics, Inc., Neoprobe Corp, Akebia Therapeutics, Inc., Adimab, LLC, Elevation Pharmaceuticals Inc.
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.